EL PASO, Texas–(BUSINESS WIRE)–Premier Biomedical, Inc. (OTCQB:
BIEI) a biotech research company focused on discovering,
developing, and commercializing medical treatments for a wide range of
diseases in humans, including innovative therapies for breast cancer,
announced today that they have consolidated and secured financing via a
convertible note with restricted shares per tranche to fund their
aggressive development plans through 2016, when revenues from world-wide
joint ventures are anticipated to meet their ongoing financial needs.
The financing arrangement allows Premier to remove old debt from its
books and consolidate financing with a single funding source, while
meeting its medium-term cash needs.
William A. Hartman, President and CEO of Premier stated, “We are pleased
to be able to get our financing needs for the coming year behind us via
non-toxic means so we can concentrate on moving the company forward,
growing our technology, and expanding our reach globally, facilitating
revenue generation and mid-term self-funding.”
Chardan Capital Markets acted as placement agent for this transaction.
Contact William Hartman at (724) 633-7033, PR@premierbiomedical.com.
About Premier Biomedical, Inc.
Biomedical, Inc. (OTCQB: BIEI)
is a research-based company that intends to discover and develop medical
treatments for a wide range of diseases in humans. Premier has obtained,
via license agreements, the technology behind multiple provisional
patents in the United States and a PCT Europe National Patent. Founded
in 2010, Premier has partnered with the Department of Defense with
Center of Expertise at the William Beaumont Army Medical Center. The
companys Ramp;D efforts are centered in El Paso, TX. The Company is a
fully-reporting issuer whose common stock trades on the OTCQB
marketplace maintained by OTC Markets Group, Inc. under the ticker
For more information, visit our website http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as
defined in the Private Securities Litigation Reform Act of 1995).
Premier Biomedical, Inc. cautions that statements, and assumptions made
in this news release constitute forward-looking statements and makes no
guarantee of future performance. Forward-looking statements are based on
estimates and opinions of management at the time statements are made.
These statements may address issues that involve significant risks,
uncertainties, estimates made by management. Actual results could differ
materially from current projections or implied results. Premier
Biomedical, Inc. undertakes no obligation to revise these statements
following the date of this news release.